Friday 6 November 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
335.26
22.24
+7.10%
Follow CRL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 5 | 8 |
| (4.35%) | (6.01%) | (7.69%) | 1.21% | ||
| (1.97%) | (2.41%) | (3.16%) | 0.54% | ||
ROIC |
0.31% | 0.81% | 1.07% | 1.81% | |
Return on Tangible Assets |
(7.28%) | (9.69%) | (12.62%) | 2.07% | |
Average Days of Receivables |
64.44 | 63.47 | 64.96 | 67.49 | |
Free Cash Flow per Share |
10.46 | 7.99 | 7.72 | 8.36 | |
Free Cash Flow |
518.49 | 391.29 | 370.61 | 399.63 | |
Capital Expenditures |
(219.15) | (215.74) | (211.54) | (222.77) | |
| Other line items | |||||
Cash ROIC |
9.39% | 6.74% | 6.55% | 6.80% | |
Accounts Receivable Turnover |
5.62 | 5.53 | 5.41 | 5.41 | |
Accounts Payable Turnover |
18.62 | 19.25 | 18.78 | 16.88 | |
Inventory Turnover |
9.32 | 8.39 | 8.60 | 8.52 | |
Average Days of Payables |
20.17 | 17.93 | 19.11 | 19.89 | |
Days of Inventory on Hand |
40.55 | 48.15 | 46.94 | 44.00 | |
Tax Rate |
0.43 | 0.11 | 0.29 | (1.42) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.51% | 18.00% | 19.06% | 18.23% | |
Share Based Compensation of Revenue |
1.77% | 1.99% | 2.08% | 2.03% | |
Interest Coverage |
0.24 | 0.66 | 0.85 | 1.45 | |
Operating CF/Net income |
(5.11) | (3.29) | (2.44) | 15.49 | |
Depreciation/Fixed assets |
0.34 | 0.34 | 0.31 | 0.30 | |
Capex/Depreciation |
(0.39) | (0.42) | (0.46) | (0.50) | |
Revenue per Share |
81.01 | 82.27 | 83.28 | 83.19 | |
Operating CF per Share |
14.88 | 12.40 | 12.12 | 13.02 | |
Capex per Share |
(4.42) | (4.41) | (4.41) | (4.66) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.06 |
Columns are period end dates · fundamentals updated 5 Nov 2026